MELBOURNE, Fla., Jan. 20, 2017 /PRNewswire/ -- EMX Advanced Technologies, LLC (EMXAT) today announced that it has successfully achieved a significant scientific milestone toward the development of the company's Real-Time Laser Spectroscopy (RTLS) line of Quantum Cascade Laser (QCL) driven devices that are designed to provide early detection of diseases and other homeland safety and hospital environmental monitoring applications where volatile organic compounds (VOC's) are present, all through novel, non-invasive analysis.

As a result of internal testing, the company believes that they are the first to successfully demonstrate a commercially viable laser, with the specific characteristics needed, in the mid-IR spectrum that will be able to operate at room temperature. In addition, they have innovations that eliminate the need for a mass-spectrometer (and/or other secondary "detection only" component) to detect the volatiles of interest in all three application pillars. These break-through innovations are required to detect VOC's shown to be relevant in the early stage detection of certain cancers, hospital acquired infections and the presence of explosives.

"We believe that achieving this major milestone increases our confidence in bringing the company's RTLS detection device to commercial reality as these novel advancements will form the core of the company's RTLS device that would enable a more accessible and less expensive detection method versus currently available diagnostic tests," says EMXAT's co-founder Mr. James Herrmann, a renowned product engineer and winner of the U.S. Department of Defense's Cogswell Award.

Further, the company believes that these key innovations will enable the QCL component of EMXAT's RTLS device to potentially measure diagnostic amounts of VOC's (Volatile Organic Compounds) necessary to accurately and rapidly screen for life-threatening malignant and infectious diseases non-invasively, thereby increasing quality of life/health outcomes and significantly reducing healthcare cost for these diseases. According to EMXAT's Chief Medical Officer, Dr. John Ruckdeschel – an internationally recognized lung cancer authority, and former Director of the Moffitt Cancer Center in Tampa, Florida – "VOC analysis has already been shown to have utility in several malignancies and pulmonary disorders, but current devices are not portable, are limited in analytic scope, and require significant delays before results are known to the physician. Once fully developed, the RTLS device would represent an advancement in early detection, diagnosis and disease monitoring, which can be delivered non-invasively, in real time, in the physician's office."

Medical Research Homepage